India sets 2026 health agenda: Drug quality, innovation, TB and obesity take centre stage
“Smaller manufacturers will need to invest in upgraded facilities… Yet, these changes are necessary to reduce operational risks, minimize recalls and ensure consistent product quality,” said Parag Bhatia, director of Laborate Pharmaceuticals, a maker of generic medicines in Panipat, Haryana. The concern remains, however, whether the large number of small units in India have the wherewithal, both financial and technical, to do so, he added.
Post Comment